NCT06678919Recruiting
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
Source: ClinicalTrials.gov · Last updated 10 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 6 Nov 2024
- Start date
- 31 Oct 2024
- Primary completion date
- Dec 2034
- Lead sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Diseases
- Colorectal cancer
- NCT number
- NCT06678919
What you commit to
- Study type: Observational
- Planned participants: 500
- From 31 Oct 2024 to the primary completion date, Dec 2034
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Due to the non-interventional design of this registry, there are no specific exclusion criteria
Who the study is looking for
- patients ≥ 18 years with tissue-based diagnosis of mCRC
- ≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1- therapy (in case of MSI/MMRd) . (Exception: Patients who have received mFOLFOXIRI +/- anti-VEGF or anti- EGFR- 1L therapy or patients with ineligibility to receive 5-FU, oxaliplatin or irinotecan can be included after 1st line.)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ordensklinikum Linz, BHS - Interne I Coordinator of this site? Confirm its status | Linz | Austria | Recruiting |
| KUK Linz - Med Campus III.: Univ.-Klinik für Hämatologie und Internistische Onkologie Coordinator of this site? Confirm its status | Linz | Austria | Recruiting |
| LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie) Coordinator of this site? Confirm its status | Rankweil | Austria | Recruiting |
| Department of Internal Medicine III, Paracelsus Medical University Salzburg Coordinator of this site? Confirm its status | Salzburg | Austria | Recruiting |
| Klinikum Steyr: Innere Medizin II: Onkologie, Gastroenterologie, Angiologie Coordinator of this site? Confirm its status | Steyr | Austria | Recruiting |
| Klinikum Wels: Abteilung für Innere Medizin IV Coordinator of this site? Confirm its status | Wels | Austria | Recruiting |
| KH Zams: Innere Medizin Internistische Onkologie und Hämatologie Coordinator of this site? Confirm its status | Zams | Austria | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.